Send to

Choose Destination
J Clin Oncol. 2014 Mar 10;32(8):783-90. doi: 10.1200/JCO.2013.49.3726. Epub 2014 Feb 10.

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

Author information

J. Gregory Cairncross, University of Calgary, Calgary, Alberta; Luis Souhami, McGill University, Montreal, Quebec; Normand J. Laperriere, University of Toronto, Toronto, Ontario, Canada; Meihua Wang, American College of Radiology, Philadelphia, PA; Robert B. Jenkins, Caterina Giannini, and Jan C. Buckner, Mayo Clinic, Rochester, MN; Edward G. Shaw, Wake Forest School of Medicine, Winston-Salem, NC; David G. Brachman, Arizona Oncology Services Foundation/Barrow Neurological Institute, Phoenix, AZ; Karen L. Fink, Baylor University, Dallas, TX; Jason T. Huse, Memorial Sloan-Kettering Cancer Center, New York, NY; Minesh P. Mehta, Northwestern University, Chicago, IL; and Walter J. Curran Jr, Emory University, Atlanta, GA.



Patients with 1p/19q codeleted anaplastic oligodendroglial tumors who participated in RTOG (Radiation Therapy Oncology Group) 9402 lived much longer after chemoradiotherapy (CRT) than radiation therapy (RT) alone. However, some patients with noncodeleted tumors also benefited from CRT; survival curves separated after the median had been reached, and significantly more patients lived ≥ 10 years after CRT than RT. Thus, 1p/19q status may not identify all responders to CRT.


Using trial data, we inquired whether an IDH mutation or germ-line polymorphism associated with IDH-mutant gliomas identified the patients in RTOG 9402 who benefited from CRT.


IDH status was evaluable in 210 of 291 patients; 156 (74%) had mutations. rs55705857 was evaluable in 245 patients; 76 (31%) carried the G risk allele. Both were associated with longer progression-free survival after CRT, and mutant IDH was associated with longer overall survival (9.4 v 5.7 years; hazard ratio [HR], 0.59; 95% CI, 0.40 to 0.86; P = .006). For those with wild-type tumors, CRT did not prolong median survival (1.3 v 1.8 years; HR, 1.14; 95% CI, 0.63 to 2.04; P = .67) or 10-year survival rate (CRT, 6% v RT, 4%). Patients with codeleted mutated tumors (14.7 v 6.8 years; HR, 0.49; 95% CI, 0.28 to 0.85; P = .01) and noncodeleted mutated tumors (5.5 v 3.3 years; HR, 0.56; 95% CI, 0.32 to 0.99; P < .05) lived longer after CRT than RT.


IDH mutational status identified patients with oligodendroglial tumors who did (and did not) benefit from alkylating-agent chemotherapy with RT. Although patients with codeleted tumors lived longest, patients with noncodeleted IDH-mutated tumors also lived longer after CRT.

[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Publication types

MeSH terms


Grant support

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center